We are live on ! Find out more
ES

Enavate Sciences Portfolio holdings

AUM $352M
1-Year Est. Return 220.14%
This Fund
S&P 500
This Quarter Est. Return
-27.33%
1 Year Est. Return
+220.14%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$133M
AUM Growth
-$6.52M
Cap. Flow
+$52.9M
Cap. Flow %
39.84%
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SION
Sionna Therapeutics
SION
+$40.5M
2
IMNM icon
Immunome
IMNM
+$12.4M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMNM icon
1
Immunome
IMNM
$2.61B
$32.1M 24.18%
4,768,583
+1,290,322
+37% +$12.4M
ZBIO
2
Zenas BioPharma
ZBIO
$2.06B
$29.7M 22.39%
3,761,359
– –
SION
3
Sionna Therapeutics
SION
$2.06B
$25.9M 19.53%
+2,478,030
New +$40.5M
CAMP icon
4
CAMP4 Therapeutics
CAMP
$180M
$15.1M 11.41%
3,785,802
– –
UPB
5
Upstream Bio Inc
UPB
$350M
$15.1M 11.34%
2,459,703
– –
CMPX icon
6
Compass Therapeutics
CMPX
$360M
$14.8M 11.15%
7,788,150
– –

Similar funds

HIA
HTG Investment Advisors New Canaan, Connecticut $352M AUM 17.26% 1-Year Est. Return
AW
Alaethes Wealth Glenbrook, Nevada $351M AUM 22.79% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
PIC
PCJ Investment Counsel Toronto, Ontario, Canada $352M AUM 68.32% 1-Year Est. Return
FFO
Fiduciary Family Office Boca Raton, Florida $351M AUM 22.19% 1-Year Est. Return
EC
Elmind Capital New York $352M AUM
SMC
Spider Management Company Richmond, Virginia $351M AUM 18.35% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Enavate Sciences's Q1 2025 Portfolio in Review

As of Q1 2025, Enavate Sciences held 6 positions worth $133M, down 4.7% from $139M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Enavate Sciences deployed $52.9M of net new capital in Q1 2025, opening 1 new position and adding to 1 existing holding. Its largest new stake was Sionna Therapeutics: 2,478,030 shares worth $25.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Enavate Sciences's largest Q1 2025 buy was Sionna Therapeutics: 2,478,030 shares worth $25.9M.
  • Enavate Sciences added most to Immunome in Q1 2025, an estimated $12.4M increase.
  • Enavate Sciences's ten largest holdings make up 100% of its $133M portfolio in Q1 2025.
  • Enavate Sciences opened 1 new position and closed 0 in Q1 2025.
  • Enavate Sciences's portfolio value fell 4.7% quarter-over-quarter to $133M.

Based on Enavate Sciences's 13F filing for Q1 2025, filed 15 May 2025.